Skip to search formSkip to main contentSkip to account menu

Risedronate

Known as: Risedronsäure, RISE, 1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate 
A synthetic pyridinyl bisphosphonate agent. Risedronate binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption… 
National Institutes of Health

Related topics

Related topics

12 relations

Narrower (4)

ActonelNE 58095risedronate sodiumrisedronate sodium 30 MG Oral Tablet
DiphosphonatesDrug AllergyEsophageal AchalasiaHypocalcemia

Broader (1)

risedronic acid

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Secondary osteoporosis in long‐term bedridden patients with cerebral palsy
Background: The aim of the present paper was to investigate 20 pediatric patients with cerebral palsy and secondary osteoporosis… 
Highly Cited
2007
Highly Cited
2007
Bone Quality: An Empty Term
Although the concept of “bone quality” is at least 15 years old [1], the term has recently sparked much discussion and debate… 
Review
2007
Review
2007
Update on osteoporosis management in long-term care: focus on bisphosphonates.
Highly Cited
2007
Highly Cited
2007
Synthesis and Biological Evaluation of α-Halogenated Bisphosphonate and Phosphonocarboxylate Analogues of Risedronate
α-Halogenated analogues of the anti-resorptive bisphosphonate risedronate (5, Ris) and its phosphonocarboxylate cognate (7, 3… 
Review
2007
Review
2007
Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical Analysis
A REPORT WAS PUBLISHED in 2003 entitled “Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With… 
Highly Cited
2006
Highly Cited
2006
Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes.
Bisphosphonates are a class of molecules in widespread use in treating bone resorption diseases and are also of interest as… 
Highly Cited
2002
Highly Cited
2002
A Comparison of the Effect of Risedronate and Etidronate on Lumbar Bone Mineral Density in Japanese Patients with Osteoporosis: A Randomized Controlled Trial
Abstract: To demonstrate the clinical benefit of 2.5 mg daily risedronate in the treatment of involutional osteoporosis, the… 
Highly Cited
2001
Highly Cited
2001
Risedronate Pharmacokinetics and Intra- and Inter-Subject Variability Upon Single-Dose Intravenous and Oral Administration
AbstractPurpose. To determine the pharmacokinetics and absolute bioavailability of risedronate after single-dose oral… 
Review
2000
Review
2000
Oral bisphosphonates
This study was conducted to review the efficacy and safety of oral bisphosphonates for the treatment of bone metastases in cancer… 
Highly Cited
2000
Highly Cited
2000
Dose‐Proportional Pharmacokinetics of Risedronate on Single‐Dose Oral Administration to Healthy Volunteers
Risedronate is a pyridinyl bisphosphonate approved for the treatment of Paget's disease (US‐FDA) and in development for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)